Form 8-K - Current report:
SEC Accession No. 0001104659-24-116346
Filing Date
2024-11-12
Accepted
2024-11-12 07:17:37
Documents
15
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2427736d1_8k.htm   iXBRL 8-K 30521
2 EXHIBIT 99.1 tm2427736d1_ex99-1.htm EX-99.1 52521
6 GRAPHIC tm2427736d_ex99-1img001.jpg GRAPHIC 3246
  Complete submission text file 0001104659-24-116346.txt   273133

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA zbio-20241112.xsd EX-101.SCH 3015
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE zbio-20241112_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE zbio-20241112_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2427736d1_8k_htm.xml XML 3796
Mailing Address 1000 WINTER ST, SUITE 1200 WALTHAM MA 02451
Business Address 1000 WINTER ST, SUITE 1200 WALTHAM MA 02451 857-271-2954
Zenas BioPharma, Inc. (Filer) CIK: 0001953926 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42270 | Film No.: 241443259
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)